J Natl Med Assoc. 2009 Aug;101(8):761-4
Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer.
Coskun U, Alkis N, Celenkoglu G, Buyukberber S, Ozkan M, Camci C, Uner A, Er O, Aslan UY, Sevinc A, Tokluoglu S, Ozturk B, Yildiz R, Benekli M; Anatolian Society of Medical Oncology.
Department of Medical Oncology, Gazi University Medical School, Besevler, Ankara 06500, Turkey.
aim of the study was to evaluate the efficacy and tolerability of
gemcitabine and uracil-tegafur (UFT) combination in patients with
advanced pancreatic carcinoma, retrospectively. Thirty-one patients,
including 27 with metastatic disease, were treated with gemcitabine at
a dose of 1000 mg/m2 in 30 minutes on days 1 and 8, and oral UFT 300
mg/m2 on days 1-14, as the first-line regimen in advanced stage. The
cycle was repeated every 21 days. A total of 116 cycles of chemotherapy
were administered, with a median of 3 cycles per patient (range 1-13).
The objective response rate was observed in 6 (19.3%) patients with 1
(3.2%) complete response, and 5 (16.1%) partial responses. The median
response duration was 4 (range, 3-14) months. Eight (25.8%) patients
had a standard deviation of more than 3 months. Median overall survival
was 8 months (95% CI, 6-10 months) and median time to progression was
4.2 months (95% CI, 1-6 months). This combination was generally well
tolerated. There were no life-threatening side effects. Most common
toxicities were of hematologic and gastrointestinal nature. In
conclusion, this regimen was well tolerated and seemed to have a
moderate activity in the palliative treatment of advanced pancreatic